Accidental Ixazomib Overdose in a Patient With Multiple Myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33980053/
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of oral chemotherapeutic agents for the managemen ...
-
Mark FeslerMay 24, 2021Valuable piece as our best intended instructions don’t always “reach” the patient and while hopefully uncommon, this can be a resource for a practicing clinician
-
Multiple Myeloma ConnectMay 24, 2021Please share your thoughts concerning overdose on oral chemotherapy.
-
Naveed Saleh, MD, MS – Skipta TeamMay 24, 2021Please feel free to share your concerns about and professional experiences with overdose on oral chemotherapy.